PROJECT 2: Repeat derepression and RNA-mediated toxicity in FSHD Abstract FSHD is caused by somatic derepression of the normally transcriptionally silent D4Z4 locus and subsequent expression of the disease gene DUX4. The broad and long-term goal of this project is to identify molecular pathways downstream of D4Z4 derepression that may be targeted to slow disease progression or improve muscle function. The major hypothesis of this project is that repetitive and other aberrant RNAs contribute to DUX4 cytotoxicity and modify FSHD severity. The specific goal of the project is to identify the mechanistic origins of aberrant RNA production and cytotoxicity, and determine whether these toxic RNAs modify FSHD penetrance. This will be accomplished by:
Aim 1, Determine the molecular mechanisms of DUX4-mediated inhibition of RNA surveillance;
Aim 2, Determine the subset of DUX4-induced RNAs that are actively translated, and test whether these aberrant RNAs produce abnormal proteins or novel peptides in DUX4-expressing cells;
Aim 3, Determine whether genetic variation influences repetitive RNA expression to modify FSHD penetrance. Together, these aims will identify mechanisms that promote stable expression of repetitive and other aberrant RNAs, thereby contributing to DUX4 toxicity and acting as a novel modifier of FSHD penetrance. The significance of these studies is that they will identify molecular pathways downstream of D4Z4 derepression that mediate DUX4 toxicity and contribute to variable penetrance of FSHD. The health relatedness is that RNA-mediated mechanisms of toxicity may provide opportunities for therapeutic intervention downstream of D4Z4 derepression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
2P01NS069539-06A1
Application #
8998516
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2015-09-30
Budget End
2016-09-29
Support Year
6
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Lemmers, Richard J L F; van der Vliet, Patrick J; Vreijling, Jeroen P et al. (2018) Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Hum Mol Genet 27:3488-3497
Lim, Jong-Won; Wong, Chao-Jen; Yao, Zizhen et al. (2018) Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures. Hum Mol Genet :
Lemmers, Richard Jlf; van der Vliet, Patrick J; Balog, Judit et al. (2018) Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2. Eur J Hum Genet 26:94-106
Balog, Judit; Goossens, Remko; Lemmers, Richard J L F et al. (2018) Monosomy 18p is a risk factor for facioscapulohumeral dystrophy. J Med Genet 55:469-478
Campbell, Amy E; Shadle, Sean C; Jagannathan, Sujatha et al. (2018) NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins. Elife 7:
de Greef, Jessica C; Krom, Yvonne D; den Hamer, Bianca et al. (2018) Smchd1 haploinsufficiency exacerbates the phenotype of a transgenic FSHD1 mouse model. Hum Mol Genet 27:716-731
Campbell, Amy E; Belleville, Andrea E; Resnick, Rebecca et al. (2018) Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. Hum Mol Genet 27:R153-R162
Mul, Karlien; Heatwole, Chad; Eichinger, Katy et al. (2018) Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study. Muscle Nerve 58:213-218
Hendrickson, Peter G; DorĂ¡is, Jessie A; Grow, Edward J et al. (2017) Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. Nat Genet 49:925-934
Campbell, Amy E; Oliva, Jonathan; Yates, Matthew P et al. (2017) BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. Skelet Muscle 7:16

Showing the most recent 10 out of 53 publications